Michele Danaher, MD
Family Medicine · Mokena, ILNPI 1679561773
Payments from drug & device makers
Across 94 payments — averaging $15.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$455
- Boehringer Ingelheim$160
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$94
- Novo Nordisk$87
- Lilly USA, LLC$67
- Takeda Pharmaceuticals U.S.A., Inc.$59
- plus $496 from 16 others
What the payments were for
- Food & beverage$1,418100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $455 |
| Boehringer Ingelheim | 8 | $160 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $94 |
| Novo Nordisk | 5 | $87 |
| Lilly USA, LLC | 5 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| AstraZeneca | 4 | $52 |
| GSK | 3 | $52 |
| Pfizer | 3 | $50 |
| Abbott | 3 | $48 |
| Amarin Pharma, Inc. | 3 | $42 |
| Nestle Healthcare Nutrition Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Merck | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Novartis | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Bausch Health US, LLC | 1 | $14 |
| Edwards Lifesciences | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,418 in reported general payments places this provider in the 75th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $95,181 |
| EliquisApixaban | 52 | $65,344 |
| JanuviaSitagliptin Phosphate | 35 | $49,244 |
| MyrbetriqMirabegron | 26 | $31,539 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $25,228 |
| XareltoRivaroxaban | 15 | $24,707 |
| ProliaDenosumab | 11 | $19,149 |
| LinzessLinaclotide | 11 | $17,410 |
| JardianceEmpagliflozin | 18 | $10,670 |
| Mirabegron ErMirabegron | 14 | $8,468 |
| Levothyroxine Sodium | 586 | $7,484 |
| Atorvastatin Calcium | 751 | $7,085 |
| DuleraMometasone/Formoterol | 11 | $4,784 |
| SynthroidLevothyroxine Sodium | 41 | $3,762 |
| Losartan Potassium | 341 | $3,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $87 | $95,18175 claims |
| PfizerEliquis | $50 | $65,34452 claims |
| MerckJanuvia, Dulera | $22 | $54,02846 claims |
| GSKTrelegy Ellipta | $52 | $25,22817 claims |
| AbbVieLinzess, Synthroid | $455 | $21,17252 claims |
| Boehringer IngelheimJardiance | $160 | $10,67018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Mokena
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.